**Profitability:** Autolus Therapeutics has a higher gross profit margin than ZIVO Bioscience. This suggests that Autolus is more efficient in converting its sales into profits. However, Autolus’s operating margin is lower than ZIVO Bioscience’s, indicating that it may be more expensive to run its operations.

The company’s lead product candidate, CAR T-cell therapy, is designed to target specific cancer cells and is currently undergoing clinical trials. About Zivo Bioscience (Get Free Report) Zivo Bioscience, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel therapies for the treatment of cancer and other diseases. Zivo’s lead product candidate, a novel antibody-drug conjugate (ADC), is currently undergoing clinical trials.

* **Proprietary Algae Cultures:** ZIVO’s core strength lies in its proprietary algae cultures, which are cultivated in controlled environments. These cultures are specifically designed to produce high-quality bioactive ingredients. * **Sustainable Production:** ZIVO’s algae cultivation practices are environmentally friendly and sustainable. They utilize renewable resources and minimize waste. * **Diverse Product Portfolio:** ZIVO offers a wide range of natural bioactive ingredients, catering to various applications in animal, human, and dietary supplement industries. * **Licensing and Sales:** ZIVO primarily operates through licensing agreements with manufacturers, allowing them to access ZIVO’s proprietary algae cultures and bioactive ingredients.